Pharmaceutical company Mayne Pharma Group Limited (ASX:MYX) said on Thursday that it has launched its butalbital acetaminophen and caffeine (BAC) capsule in 50mg/300mg/40mg in the United States for the treatment of tension headache (migraine).
It comes after the company received approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application for BAC.
US sales of BAC capsule 50mg/300mg/40mg were approximately USD40m for the 12 months ending 31 March 2020, according to IQVIA.
Mayne Pharma markets more than 60 generic and specialty branded pharmaceuticals in the US.
Endo International names new non-executive director
The FDA provides update of COVID-19
US FDA Approves Abbreviated NDA for Heparin Sodium
Cipla receives US FDA approval for Icatibant Injectable 30mg/3mL
Amneal unveils FDA approved generic fluphenazine for treating schizophrenia
Amneal Launches Generic Fluphenazine Following ANDA Approval by FDA
US FDA approves Mylan and Fujifilm Kyowa Kirin Biologics' Hulio
CEBINA identifies antihistamine nasal spray Azelastine as potential anti-COVID-19 approach
Sandoz signs long-term manufacture and distribution agreement with Civica Rx